Paratek Pharmaceuticals Inc (NASDAQ:PRTK) CFO Douglas W. Pagan sold 5,237 shares of the firm’s stock in a transaction on Monday, April 9th. The shares were sold at an average price of $12.70, for a total value of $66,509.90. Following the completion of the sale, the chief financial officer now directly owns 77,083 shares in the company, valued at approximately $978,954.10. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Shares of PRTK opened at $13.65 on Friday. Paratek Pharmaceuticals Inc has a 52 week low of $11.85 and a 52 week high of $29.00. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.72.
Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its quarterly earnings results on Thursday, March 1st. The specialty pharmaceutical company reported ($0.78) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.75) by ($0.03). Paratek Pharmaceuticals had a negative net margin of 706.00% and a negative return on equity of 93.16%. The firm had revenue of $5.07 million during the quarter, compared to the consensus estimate of $5.00 million. research analysts predict that Paratek Pharmaceuticals Inc will post -3.44 EPS for the current year.
A number of equities research analysts have weighed in on the company. Cantor Fitzgerald set a $50.00 target price on Paratek Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, January 3rd. ValuEngine downgraded Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, December 29th. Zacks Investment Research raised Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 target price on the stock in a report on Wednesday, January 10th. Finally, Leerink Swann reiterated an “outperform” rating on shares of Paratek Pharmaceuticals in a research note on Sunday, March 4th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $40.00.
COPYRIGHT VIOLATION WARNING: This piece was originally posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://dakotafinancialnews.com/2018/04/13/insider-selling-paratek-pharmaceuticals-inc-prtk-cfo-sells-66509-90-in-stock-2.html.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.